25 August 2020 - Some outcomes are not clear.

• The PBAC recommended the listing of the fixed dose combination of beclomethasone dipropionate with eformoterol fumarate dihydrate (Fostair) for the maintenance treatment of asthma. The PBAC did not recommend the listing of beclomethasone dipropionate with eformoterol fumarate dihydrate for asthma maintenance and reliever therapy. What does it mean? There appear to be two outcomes here; one recommendation and one rejection. One assumes the submission from Emerge Health sought a listing for both; the agenda is not clear on this. Why doesn't the apparent rejection appear as a rejection?
• The PBAC recommended the listing of daratumumab for use in combination with bortezomib and dexamethasone for the second-line treatment for patients with multiple myeloma. The PBAC noted that daratumumab monotherapy would be provided by the sponsor to all eligible patients with relapsed and/or refractory multiple myeloma who have no other PBS funded treatment options on a compassionate basis. Is this an outcome? The agenda indicates that Janssen only sought a listing for daratumumab for use in combination with bortezomib and dexamethasone. The PBAC rejected Janssen's submission for the use of daratumumab as monotherapy back in March 2019; it appears as though they have given up here.